You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of novel malaria parastie metabolite-based non-invasive diagnostic biosensor

    SBC: GUILD ASSOCIATES INC            Topic: N/A

    The long term goal of the project is to use malaria parasite specific low-molecular-weight metabolites as biomarkers for development of sensitive, low-cost, simple, battery-operated field-deployable urine or saliva diagnostic biosensor for detection of malaria infection. Four malaria parasite-specific metabolites (3-Methylindole, Succinylacetone, S-Methyl-L-thiocitrulline, O-Arachidonoyl Glycidol ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. SBIR Phase II: Optimization of Rotavirus Vaccine Production

    SBC: Meridian Life Sciences, Inc.            Topic: N/A

    To improve the safety and efficacy of oral rotavirus vaccines, CDC scientists have developed a proprietary inactivated rotavirus vaccine (IRV) technology (new human strains and a novel method for rotavirus inactivation) and demonstrated the immunogenicity in mice [14] and protective efficacy in piglets [15] of this IRV by intramuscular (IM) administration. More recently, CDC scientists have demons ...

    SBIR Phase II 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. Clear Cues: Supportive Wayfinding for Care Communities

    SBC: Linda-&-Cameron, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): The purpose of this project is to develop and test Clear Cues (CC), a signage system for care communities that supports way finding in people with dementia. Way finding is a process through which people use informationin the environment to help them get to their desired destination. It's both the user experience of choosing a path and the design elements t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Alzheimer's Disease Drug Treatment

    SBC: P2D, INC            Topic: NIA

    DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (AD). The core symptom of AD is short-term memory impairment. (DSM-IV) In preliminary studies, PD2XXX improved short term memory by over 110% in a well-accepted triple transgenic mouse model of AD (3xTg ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A biomarker of aging as a predictor of kidney transplant function

    SBC: HEALTHSPAN DIAGNOSTICS, LLC            Topic: NIA

    ABSTRACT The number of kidney transplant candidates on the waiting list continues to increase each year, while the number of kidney donations remains stagnant. The enduring donor shortage compels clinicians to use kidneys from marginal donors, referred toas expanded criteria donors (ECD). ECD kidneys, obtained primarily from older donors, have a higher risk of delayed graft function and graft loss ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes.

    SBC: Mycosynthetix, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Title: Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes Project Summary/Abstract It is estimated that over 2 billion people worldwide are suffering from complications due to infections withsoil transmitted helminthes (STHs), but very little research is being conducted by human health pharmaceutical companies. In the USA, it is estim ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Biosensor Assays for Diagnosis of Chronic HCV Infection

    SBC: ALDERON BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR application is submitted in response to the call by DHHS for new tests for qualitative measurement of HCV RNA for diagnosis of chronic HCV infection in patients. The need is for HCV RNA assays that areas reliable but less expensive and resource-demanding than current molecular assays. The new test proposed for research and development consists ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A novel antisense therapeutic for treatment of Aspergillus fumigatus infections

    SBC: GUILD ASSOCIATES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Guild proposes to develop an antisense oligomer-based antifungal effective against the human pathogen Aspergillus fumigatus. With a 40%-60% mortality rate, invasive aspergillosis (IA) due to A. fumigatus now surpasses invasive candidiasis as the most frequent fungal cause of death, especially amongst immunocompromised patients. Successful therapy for IA with cu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Cell analysis and immunoassay device for distributed HIV diagnosis and monitoring

    SBC: INDEXUS BIOMEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this research is to develop a new approach to bring diagnosis and monitoring tests for HIV to the primary care level (primary care provider office, small healthcare clinics and labs, and community health center labs) by introducing a multi-functional cell analysis and immunoassay platform that is portable, low cost and easy to use. It will allow pat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of Novel Cyclophilin D Inhibitors for Mitochondrial Disease Therapy

    SBC: SCYNEXIS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Myopathies and other clinical disorders arising from genetic abnormalities of the mitochondrial respiratory chain collectively affect as many as 1 in 8000 individuals, representing in aggregate a significant disease burden, even though the specific underlying genetic lesions are each quite rare. Despite the need for therapeutic strategies to prevent or slow the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government